Pulmonology

CTD-ILD

Questions discussed in this category

Would you initiate antifibrotic therapy in a patient with CTD-ILD experiencing worsening symptoms and declining lung function, despite no clear evidence of fibrosis on CT scans?

CT changes are subsolid and ground glass nodules.

2 Answers available

What are your thoughts on using abatacept for RA-associated ILD in a patient undergoing treatment for CLL with zanubrutinib, and how would you assess the potential increased risk of infection in this context?

1 Answer available

What factors would encourage you to choose abatacept vs tocilizumab in a patient with RA-ILD with a UIP pattern of pulmonary fibrosis?

2 Answers available

Do you ever consider tapering off steroid-sparing agents in patients with stable non-IPF ILD?

1 Answer available

How do you screen rheumatoid arthritis patients for lung disease (modality, frequency, patient selection)?

This question is part of our collaboration with ACR Convergence 2024 to Continue the Conversation from the meeeting. This question was inspired by the...

5 Answers available

How do you approach management of ILD in the presence of weakly positive RF and ANA but no other objective systemic findings of connective tissue disease?

Is this managed as CTD-ILD with immunosuppressive +/- anti-fibrotic agents?

1 Answer available

In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?

1 Answer available

Would you add abatacept to treat active inflammatory arthritis in a patient with history of RA-ILD who is already taking mycophenolate?

1 Answer available

What is your approach to management of pulmonary fibrosis in patients with a history of microscopic polyangiitis who do not have other active organ involvement?

Patient is with past history of glomerulonephritis in remission after rituximab for the past 2 years. +MPO/P-ANCA

1 Answer available

What dose and duration of steroid therapy do you employ while starting mycophenolate in an outpatient with relatively stable CTD-ILD?

Do you ever start mycophenolate without steroids?

1 Answer available

In light of the RECITAL study, would rituximab be a reasonable choice in a patient with PL-12 antibodies, rapidly progressive pulmonary disease with organizing pneumonia on biopsy?

Given poor pulmonary outcomes in people with anti-PL12 antibodies, would you recommend more aggressive therapy? The patient was diagnosed with onset o...

1 Answer available

Is it safe to combine mycophenolate and adalimumab for management of pulmonary sarcoidosis in a patient that could not tolerate methotrexate?

3 Answers available

What is your approach to steroid sparing therapy in patients with suspected CTD-ILD?

2 Answers available

Do you offer immunosuppression to patients with CTD-ILD with concomitant well controlled HIV?

2 Answers available

Papers discussed in this category

Autoimmunity reviews, 2021 Apr 19

Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: A systematic literature review.

Arthritis & rheumatology (Hoboken, N.J.), 2024 Jul 08

2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.

Rheumatology international, 2023 Apr 18

Four-factor risk score for the prediction of interstitial lung disease in rheumatoid arthritis.

Autoimmunity reviews, 2024 Sep 11

Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis.

The Lancet. Respiratory medicine, 2016-09

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

Respirology, 2013 Nov 29

Rituximab in severe, treatment-refractory interstitial lung disease.

Respir Res, 2022 Jun 21

Effect size of rituximab on pulmonary function in the treatment of connective-tissue disease-related interstitial lung disease: a systematic review and meta-analysis.

J Infect Dis, 2020 Jun 11

Interstitial Lung Abnormalities in People With HIV Infection and Uninfected Controls.

Clin Chest Med, 2013 Apr 08

Interstitial lung disease in HIV.

Arthritis & rheumatology (Hoboken, N.J.), 2015-05

Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis.

International journal of rheumatic diseases, 2014-02

Neurosarcoidosis mimicking multiple sclerosis successfully treated with methotrexate and adalimumab.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2014-04-18

Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis.

Clinical nuclear medicine, 2016-05

FDG PET/CT Evidence of Effective Treatment of Cardiac Sarcoidosis With Adalimumab.

J Investig Med High Impact Case Rep, 2021 Jan-Dec

Pituitary Sarcoidosis in a Pediatric Patient Successfully Treated With Adalimumab and Methotrexate.

Clinical therapeutics, 2018 Feb

Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial.

Lancet Respir Med, 2023 Jan

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.

Rheumatology (Oxford, England), 2021 Dec 24

Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients.

Current opinion in pulmonary medicine, 2023 Jun 30

Interstitial lung disease in patients with anti-neutrophil cytoplasm antibody-associated vasculitis: an update on pathogenesis and treatment.

Rheumatology (Oxford, England), 2023 Feb 01

Interstitial lung disease in ANCA-associated vasculitis: associated factors, radiographic features and mortality.

N. Engl. J. Med., 2019 May 20

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

N Engl J Med, 2019 Sep 29

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

Rheumatology (Oxford),

The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity.

Rheumatology (Oxford, England), 2023 Dec 01

Anti-SAE autoantibody in dermatomyositis: original comparative study and review of the literature.

Rheumatology (Oxford, England), 2020 Dec 01

Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients.

Internal medicine journal, 2020 Sep

Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study.

Rheumatology international, 2016 Apr 12

Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study.

Scandinavian journal of rheumatology, 2024 Jul 25

Prognostic factors for interstitial lung disease progression in rheumatoid arthritis: May methotrexate protect against progression?

Related Topics in Pulmonology